Holen Sie sich die Stockscreener-App
0.6451
1.21%
-0.0079
Handel nachbörslich:
.63
-0.0151
-2.34%
Schlusskurs vom Vortag:
$0.653
Offen:
$0.66
24-Stunden-Volumen:
885.13K
Relative Volume:
0.82
Marktkapitalisierung:
$83.33M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-26.91M
KGV:
-2.9323
EPS:
-0.22
Netto-Cashflow:
$-19.57M
1W Leistung:
+2.30%
1M Leistung:
-20.23%
6M Leistung:
-28.32%
1J Leistung:
-30.24%
1-Tages-Spanne:
$0.6301
$0.6692
1-Wochen-Bereich:
$0.60
$0.6999
52-Wochen-Spanne:
$0.551
$1.29
Atossa Therapeutics Inc Stock (ATOS) Company Profile
Firmenname
Atossa Therapeutics Inc
Sektor
Branche
Telefon
206.588.0256
Adresse
10202 5TH AVENUE NE, SEATTLE, WA
Vergleichen Sie ATOS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
0.6451 | 84.35M | 0 | -26.91M | -19.57M | -0.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2018-01-26 | Eingeleitet | Maxim Group | Buy |
Atossa Therapeutics Inc Aktie (ATOS) Neueste Nachrichten
Will Atossa Therapeutics Inc. (YAG2) stock beat revenue estimatesWalking Comfort Picks & HOKA buying tips before checkout - ulpravda.ru
Atossa Genetics (NASDAQ:ATOS) Shares Cross Below 200 Day Moving Average – Here’s Why - Defense World
Is Atossa Therapeutics Inc. stock in correction or buying zoneJuly 2025 Outlook & Community Verified Watchlist Alerts - ulpravda.ru
Will Atossa Therapeutics Inc. stock benefit from AI adoptionQuarterly Earnings Summary & Fast Entry Momentum Trade Alerts - ulpravda.ru
Will Atossa Therapeutics Inc. stock outperform growth indexesWeekly Stock Analysis & Verified Momentum Watchlists - ulpravda.ru
What margin trends mean for Atossa Therapeutics Inc. stockPortfolio Gains Summary & Safe Swing Trade Setups - ulpravda.ru
Is Atossa Therapeutics Inc. (YAG2) stock supported by strong fundamentalsMarket Sentiment Report & Real-Time Volume Spike Alerts - ulpravda.ru
Bearish Setup: Will Atossa Therapeutics Inc. stock maintain growth storyJuly 2025 Decliners & High Accuracy Investment Entry Signals - ulpravda.ru
FDA clears Atossa Therapeutics to begin (Z)-endoxifen study By Investing.com - Investing.com India
Atossa Therapeutics Receives FDA "Study May Proceed" Letter for - GuruFocus
Atossa Wins FDA Clearance to Advance (Z)-Endoxifen Trial - TipRanks
Atossa Therapeutics Receives FDA Approval for Metastatic Breast Cancer Study - TradingView — Track All Markets
FDA clears new breast cancer study testing (Z)-endoxifen candidate - Stock Titan
Reviewing Atossa Genetics (NASDAQ:ATOS) and Autonomix Medical (NASDAQ:AMIX) - Defense World
Seattle InnoDiagrid emerges from stealth I Atossa troubles - The Business Journals
Atossa Genetics Inc. (NASDAQ:ATOS) Sees Large Increase in Short Interest - Defense World
Atossa Genetics Inc. (NASDAQ:ATOS) Receives Consensus Recommendation of “Hold” from Analysts - Defense World
Atossa Genetics Inc. (NASDAQ:ATOS) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Atossa Genetics (NASDAQ:ATOS) Share Price Passes Below 200 Day Moving Average – Should You Sell? - Defense World
Atossa Genetics (NASDAQ:ATOS) Share Price Passes Below 200 Day Moving AverageShould You Sell? - MarketBeat
NioCorp and Atossa Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Norwich Bulletin
Atossa Genetics (NASDAQ:ATOS) & IDEXX Laboratories (NASDAQ:IDXX) Head-To-Head Survey - Defense World
Will Atossa Therapeutics Inc. stock outperform international peersChart Signals & Community Consensus Trade Alerts - Улправда
Earnings Report: Is Atossa Therapeutics Inc. stock a buy before product launchesTake Profit & Smart Money Movement Tracker - Улправда
Atossa Therapeutics Earnings Notes - Trefis
Will Atossa Therapeutics Inc. stock maintain growth storyBond Market & Free AI Powered Buy and Sell Recommendations - DonanımHaber
Will Atossa Therapeutics Inc. stock maintain momentum in 2025Quarterly Earnings Report & Technical Pattern Based Signals - Улправда
Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category - BioSpace
Atossa Therapeutics Wins R&D Excellence Award for Precision Endocrine Therapy Innovation - Clinical Trials Arena
Atossa Genetics (NASDAQ:ATOS) Stock Crosses Below Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Atossa Genetics (NASDAQ:ATOS) Stock Crosses Below Two Hundred Day Moving Average – Here’s What Happened - Defense World
Atossa Therapeutics (ATOS) Highlights Promising (Z)-endoxifen Tr - GuruFocus
Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium - WV News
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Atossa Therapeutics Stock Jumps After FDA Grants Rare Pediatric Status To DMD Drug — Retail Bets On Phase 3 Fast-Track - Stocktwits
Trade Recap: Will Atossa Therapeutics Inc stock gain from lower inflationJuly 2025 Chart Watch & Weekly Chart Analysis and Guides - moha.gov.vn
Atossa gains on rare pediatric disease status for Duchenne asset - MSN
Atossa Therapeutics, Inc. (ATOS) -6.4% in After-hours: Shares Slip Amid Routine Trading - Stocks Telegraph
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy - BioSpace
Volume Recap: Will Atossa Therapeutics Inc stock return to pre crisis levelsMarket Trend Review & Target Return Focused Picks - moha.gov.vn
Atossa Therapeutics (ATOS) Stock: Soars 8% as FDA Grants Rare Pediatric Disease Designation for (Z)-Endoxifen (ATOS) - parameter.io
Why Are Shares Of Atossa Therapeutics Up Today? - Benzinga
Atossa Therapeutics (ATOS) Surges on FDA Pediatric Designation - GuruFocus
Atossa gains on Rare Pediatric Disease status for Duchenne asset - Seeking Alpha
Atossa Therapeutics stock soars after FDA grants rare pediatric disease status - Investing.com UK
Atossa Therapeutics stock soars after FDA grants rare pediatric disease status By Investing.com - Investing.com Nigeria
Finanzdaten der Atossa Therapeutics Inc-Aktie (ATOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Atossa Therapeutics Inc-Aktie (ATOS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Remmel H. Lawrence | Director |
Mar 26 '25 |
Buy |
0.70 |
10,000 |
7,000 |
10,257 |
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):